Alnylam Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Alnylam Pharmaceuticals es Yvonne Greenstreet , nombrado en Jan 2022, tiene una permanencia de 2.83 años. compensación anual total es $8.90M, compuesta por 11% salario y 89% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.039% de las acciones de la empresa, por valor de R$75.32M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 9 años, respectivamente.

Información clave

Yvonne Greenstreet

Chief Executive Officer (CEO)

US$8.9m

Compensación total

Porcentaje del salario del CEO	11.0%
Permanencia del CEO	2.8yrs
Participación del CEO	0.04%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Yvonne Greenstreet en comparación con los beneficios de Alnylam Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$332m
Jun 30 2024	n/a	n/a	-US$73m
Mar 31 2024	n/a	n/a	-US$332m
Dec 31 2023	US$9m	US$976k	-US$440m
Sep 30 2023	n/a	n/a	-US$510m
Jun 30 2023	n/a	n/a	-US$1b
Mar 31 2023	n/a	n/a	-US$1b
Dec 31 2022	US$5m	US$850k	-US$1b
Sep 30 2022	n/a	n/a	-US$1b
Jun 30 2022	n/a	n/a	-US$981m
Mar 31 2022	n/a	n/a	-US$893m
Dec 31 2021	US$9m	US$619k	-US$853m
Sep 30 2021	n/a	n/a	-US$838m
Jun 30 2021	n/a	n/a	-US$887m
Mar 31 2021	n/a	n/a	-US$876m
Dec 31 2020	US$3m	US$622k	-US$858m
Sep 30 2020	n/a	n/a	-US$891m
Jun 30 2020	n/a	n/a	-US$846m
Mar 31 2020	n/a	n/a	-US$886m
Dec 31 2019	US$3m	US$571k	-US$886m
Sep 30 2019	n/a	n/a	-US$821m
Jun 30 2019	n/a	n/a	-US$858m
Mar 31 2019	n/a	n/a	-US$802m
Dec 31 2018	US$3m	US$540k	-US$761m
Sep 30 2018	n/a	n/a	-US$692m
Jun 30 2018	n/a	n/a	-US$570m
Mar 31 2018	n/a	n/a	-US$525m
Dec 31 2017	US$985k	US$504k	-US$491m

Compensación vs. Mercado: La compensación total de Yvonne($USD8.90M) está por encima de la media de empresas de tamaño similar en el mercado BR ($USD5.72M).

Compensación vs. Ingresos: La compensación de Yvonne ha aumentado mientras la empresa no es rentable.

CEO

Yvonne Greenstreet (61 yo)

2.8yrs

Permanencia

US$8,895,670

Compensación

Dr. Yvonne L. Greenstreet, MBChB, MBA, is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. Sh...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yvonne Greenstreet	CEO & Director	2.8yrs	US$8.90m	0.039% R$ 75.3m
Jeffrey Poulton	CFO & Executive VP	5.3yrs	US$3.22m	0.016% R$ 31.9m
Akshay Vaishnaw	Chief Innovation Officer & Member of the Scientific Advisory Board	1.1yrs	US$3.32m	0.018% R$ 35.0m
Pushkal Garg	Chief Medical Officer	10.1yrs	US$3.23m	0.0090% R$ 17.5m
Tolga Tanguler	Executive VP & Chief Commercial Officer	3.8yrs	US$2.87m	0.0054% R$ 10.4m
Timothy Maines	Chief Technical Operations & Quality Officer	1.8yrs	sin datos	sin datos
Kevin Fitzgerald	Senior VP	5.5yrs	sin datos	0.010% R$ 20.2m
Piyush Sharma	Chief Ethics & Compliance Officer	2.2yrs	sin datos	sin datos
Robert Hesslein	Chief Legal Officer & Corporate Secretary	less than a year	sin datos	sin datos
Christine Lindenboom	Chief Corporate Communications Officer	no data	sin datos	sin datos
Evan Lippman	Chief Corporate Development & Strategy Officer	2.2yrs	sin datos	sin datos
Kelley Boucher	Chief Human Resource Officer	5.5yrs	sin datos	sin datos

2.8yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de A1LN34 se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yvonne Greenstreet	CEO & Director	3.1yrs	US$8.90m	0.039% R$ 75.3m
Akshay Vaishnaw	Chief Innovation Officer & Member of the Scientific Advisory Board	no data	US$3.32m	0.018% R$ 35.0m
Muthiah Manoharan	Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board	9.1yrs	sin datos	sin datos
Peter Kellogg	Independent Director	1.7yrs	US$658.72k	0% R$ 0
Paul Schimmel	Member of the Scientific Advisory Board	no data	US$516.04k	sin datos
David E. Pyott	Independent Director	8.9yrs	US$477.21k	0.022% R$ 42.2m
Phillip Sharp	Co-Founder	22.4yrs	US$502.21k	0.21% R$ 401.3m
Amy W. Schulman	Independent Chair of the Board & Lead Independent Director	10.3yrs	US$531.36k	0.0065% R$ 12.7m
Markus Stoffel	Member of Scientific Advisory Board	no data	sin datos	sin datos
David Bartel	Member of Scientific Advisory Board	no data	sin datos	sin datos
Dennis Ausiello	Member of the Scientific Advisory Board & Independent Director	12.6yrs	US$477.21k	0.0028% R$ 5.5m
Colleen Reitan	Independent Director	6.4yrs	US$489.15k	0% R$ 0

9.0yrs

Permanencia media

69.5yo

Promedio de edad

Junta con experiencia: La junta directiva de A1LN34 se considera experimentada (9 años de antigüedad promedio).

Alnylam Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023

Alnylam Pharmaceuticals, Inc. Announces Board Changes

Alnylam Pharmaceuticals, Inc. Announces Executive Appointments

Recent updates

Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Alnylam Pharmaceuticals, Inc. Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Alnylam Pharmaceuticals, Inc. Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Alnylam Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023

Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023

Alnylam Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Alnylam Pharmaceuticals, Inc. Announces Board Changes

Alnylam Pharmaceuticals, Inc. Submits CTA Application for Aln-Khk, an Investigational RNAi therapeutic for the Treatment of Type 2 Diabetes

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration for ONPATTRO® (Patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Alnylam Pharmaceuticals, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. Presents Additional Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy At Heart Failure Society of America Annual Meeting

Alnylam Pharmaceuticals, Inc. Announces Executive Appointments

Alnylam Pharmaceuticals, Inc. Receives Approval in Europe for AMVUTTRA (Vutrisiran) for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals Announces Preliminary Phase 1 Data Supporting the Clinical Advancement of ALN-HSD

Alnylam Presents Positive Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

Alnylam Appoints Elliott Sigal, M.D., Ph.D., to Board of Directors

Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of Iga Nephropathy

Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering Rna to the Central Nervous System and Other Extrahepatic Tissues

Alnylam Pharmaceuticals, Inc. Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. Announces New Positive Results from an 18-Month Analysis of Exploratory Cardiac Endpoints in the HELIOS-A Phase 3 Study of Vutrisiran

Alnylam Pharmaceuticals, Inc. Announces That Health Canada Has Issued A Notice of Compliance (Noc) Authorizing Oxlumo™ (Lumasiran) Injection for Subcutaneous Use for the Treatment

Alnylam Pharmaceuticals, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Alnylam Pharmaceuticals, Inc. Announces Retirement of Steven Paul from Board of Directors

Alnylam Pharmaceuticals, Inc. Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran

Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

Alnylam Pharmaceuticals, Inc. to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting

Alnylam Comments on FDA Approval of Leqvio, the First Sirna (Rnai Therapeutic) Approved to Reduce LDL-C

Alnylam Pharmaceuticals, Inc. Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease

Alnylam Pharmaceuticals, Inc. Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for Oxlumo® for the Treatment of Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. Submits Marketing Authorization Application to European Medicines Agency for Investigational Vutrisiran for Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

Alnylam Pharmaceuticals, Inc. Presents Additional 9-Month Data from Helios-A Phase 3 Study of Vutrisiran at the European ATTR Amyloidosis Meeting

Alnylam Pharmaceuticals, Inc. Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Updates Revenue Guidance for the Full Year of 2021

Alnylam Pharmaceuticals, Inc. Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension

Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis